Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.40 |
| ▸ | SELE | P16581 | 1/20 | 0.40 |
| ▸ | ALOX5AP | P20292 | 11/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | DHFR | P00374 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16886118 | 0.89 | L3MBTL1 (0.47) | L3MBTL1KDM4CNPC1RAB9AICAM1 | |
| SCHEMBL16748887 | 0.89 | L3MBTL1 (0.47) | L3MBTL1KDM4CNPC1RAB9AICAM1 | |
| SCHEMBL19490547 | 0.88 | L3MBTL1 (0.44) | L3MBTL1KDM4CNPC1RAB9AICAM1 | |
| SCHEMBL16748888 | 0.85 | L3MBTL1 (0.43) | L3MBTL1KDM4CNPC1RAB9AICAM1 | |
| SCHEMBL16748886 | 0.79 | L3MBTL1 (0.39) | L3MBTL1KDM4CNPC1RAB9AICAM1 | |
| SCHEMBL2568655 | 0.79 | KDM4C (0.47) | L3MBTL1KDM4CNPC1RAB9AICAM1 | |
| SCHEMBL21069390 | 0.77 | KDM4C (0.47) | L3MBTL1KDM4CNPC1RAB9AICAM1 | |
| SCHEMBL16769969 | 0.75 | L3MBTL1 (0.42) | L3MBTL1KDM4CNPC1RAB9AICAM1 | |
| SCHEMBL26667763 | 0.74 | L3MBTL1 (0.46) | L3MBTL1KDM4CNPC1RAB9AICAM1 | |
| SCHEMBL16998553 | 0.73 | KDM4C (0.43) | L3MBTL1KDM4CNPC1RAB9AICAM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9796716-B2 | Selective inhibitors of Tec and Src protein kinase families | PHARMASCIENCE, INC. (CA) | 2017-10-24 | — | — | US | disclosed |
| US-9796716-B2 | Selective inhibitors of Tec and Src protein kinase families | PHARMASCIENCE, INC. (CA) | 2017-10-24 | — | — | US | disclosed |
| US-20150191473-A1 | PROTEIN KINASE INHIBITORS | PHARMASCIENCE, INC. (CA) | 2015-07-09 | — | — | US | disclosed |
| US-20150191473-A1 | PROTEIN KINASE INHIBITORS | PHARMASCIENCE, INC. (CA) | 2015-07-09 | — | — | US | disclosed |
| WO-2013177668-A1 | PROTEIN KINASE INHIBITORS | PHARMASCIENCE, INC. (CA) | 2013-12-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150191473-A1 | PROTEIN KINASE INHIBITORS | TEC, SRC, LCK | L3MBTL1 2550/4885KDM4C 2610/4885NPC1 4039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.